Afuco™ Anti-CD2 ADCC Therapeutic Antibody (Siplizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD2. Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-104 |
| Pricing | Inquiry |
| Host | Human |
| Target | CD2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |